IN THE CLAIMS:

Claims 2, 3, 7 – 11, 19, and 20 were previously cancelled. Claim 25 is canceled herein. Claims 1, 22, and 26 have been amended herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of the Claims:

1. (Currently amended) A composition comprising:

a recombinant fusion protein between human transforming growth factor α (hTGFα), human epidermal growth factor (hEGF), and P64k; and

~~human epidermal growth factor (hEGF); and~~

an adjuvant;

wherein said composition is able to produce a specific immune response in a subject against hTGFα and hEGF.

2. and 3. (Canceled).

4. (Previously presented) The composition according to claim 1, wherein a nucleic acid sequence encoding said fusion protein is cloned in an expression vector system and expressed in mammalian cells, bacteria, or yeast.

5. (Previously presented) The composition according to claim 4, wherein the nucleic acid sequence encoding said fusion protein is cloned in an expression vector of bacteria and expressed in E. coli.

6. (Previously presented) The composition according to claim 4, wherein the nucleic acid sequence encoding said fusion protein is cloned in an expression vector of bacteria that presents a genetic sequence coding for six histidines in the N-terminal end of P64k and is expressed in E. coli.

2

7. through 11. (Canceled).

12. (Previously presented) The composition according to claim 1, wherein the adjuvant is incomplete adjuvant of Freund.

13. (Previously presented) The composition according to claim 1, wherein the adjuvant is Al(OH)$_3$.

14. (Withdrawn) A method of immunization comprising administering the composition according to claim 1 to the subject so as to achieve specific antibodies against hTGFα.

15. (Withdrawn) The method according to claim 14, wherein anti-hTGFα antibodies are generated, which anti-hTGFα antibodies are capable of inhibiting binding of TGFα to its receptor in vitro.

16. (Withdrawn) The method according to claim 14, further comprising generating anti-hEGF antibodies.

17. (Withdrawn) The method according to claim 14, wherein anti-hTGFα antibodies are generated, which anti-hTGFα antibodies are able to recognize TGFα in human tumor biopsies.

18. (Withdrawn) A method of treating a malignant disease expressing hTGFα and other ligands of EGF-R selected from the group consisting of epidermoide breast carcinomas, prostate cancers, gastric cancers, and ovary epithelial cancer in a subject, comprising administering the composition of claim 1 to the subject.

19. and 20. (Canceled).

3

21.	(Previously presented) The composition according to claim 1, wherein the concentration of hTGFα and hEFG is between about 5µg to 1000µg per dose.

22.	(Currently amended) A composition comprising:

a recombinant fusion protein between human transforming growth factor α (hTGFα), human epidermal growth factor (hEGF), and P64k; and

~~human epidermal growth factor (hEGF); and~~

an adjuvant;

wherein said composition is able to produce a specific immune response in a subject against hTGFα and hEGF, and wherein the concentration of hTGFα and hEFG is 50µg per dose.

23.	(Previously presented) The composition according to claim 1, wherein the ratio of the adjuvant to the hTGFα is about 3 to 1 by weight.

24.	(Previously presented) The composition according to claim 1, wherein the ratio of the adjuvant to the hTGFα is about 40 to 1 by weight.

25.	(Canceled).

26.	(Currently amended) A composition for treatment of epithelial cancers responsive to human transforming growth factor α (hTGFα) and/or human epidermal growth factor (hEGF) in a subject, the composition comprising:

a recombinant fusion protein between hTGFα, hEGF, and P64k, wherein hTGFα comprises SEQ ID NO:2; and

~~hEGF; and~~

an adjuvant;

wherein the composition is able to produce a specific immune response against hTGFα and hEGF in the subject.

4